Home › Research › Drug development
GLP-1-BASED THERAPIES BEYOND DIABETES: EMERGING CLINICAL APPLICATIONS AND FUTURE PERSPECTIVES
Anna Maria Szeszko, Małgorzata Lubowiecka, Weronika Maria Czernek, Magdalena Cichorzewska, Martyna Płachta, Rafał Wojtan. Archiv Euromedica, 2026-08-29
Topic: Risk, prevention and care in population studies
Results Fifty-three sources were included. Histological improvements have been demonstrated in metabolic dysfunction-associated steatohepatitis with fibrosis, while semaglutide reduced major kidney outcomes in patients with type 2 diabetes and chronic kidney disease.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Szeszko, A. M., Lubowiecka, M., Czernek, W. M., Cichorzewska, M., Płachta, M., & Wojtan, R. (2026). GLP-1-BASED THERAPIES BEYOND DIABETES: EMERGING CLINICAL APPLICATIONS AND FUTURE PERSPECTIVES. Archiv Euromedica. https://doi.org/10.35630/2026/16/iss.4.14
Vancouver
Szeszko AM, Lubowiecka M, Czernek WM, Cichorzewska M, Płachta M, Wojtan R. GLP-1-BASED THERAPIES BEYOND DIABETES: EMERGING CLINICAL APPLICATIONS AND FUTURE PERSPECTIVES. Archiv Euromedica. 2026. doi:10.35630/2026/16/iss.4.14.
BibTeX
@article{szeszko2026-ffbf0b6d,
author = {Szeszko, Anna Maria and Lubowiecka, Małgorzata and Czernek, Weronika Maria and Cichorzewska, Magdalena and Płachta, Martyna and Wojtan, Rafał},
title = {{GLP-1-BASED THERAPIES BEYOND DIABETES: EMERGING CLINICAL APPLICATIONS AND FUTURE PERSPECTIVES}},
journal = {Archiv Euromedica},
year = {2026},
doi = {10.35630/2026/16/iss.4.14},
url = {https://doi.org/10.35630/2026/16/iss.4.14}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results Fifty-three sources were included.
- Histological improvements have been demonstrated in metabolic dysfunction-associated steatohepatitis with fibrosis, while semaglutide reduced major kidney outcomes in patients with type 2 diabetes and chronic kidney disease.
Why it matters
This review of GLP-1-based therapies reports histological improvement in a liver condition and reduced kidney outcomes in people with type 2 diabetes and chronic kidney disease. It reports no findings about treating, curing or preventing Alzheimer's disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designmeta-analysis
- Evidence strengthHigh
How this study scored 44/100
Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies. Scored zero for sample size, effect reported and studied in people because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 42 of the 96 points we could judge it on, which is 44 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Archiv Euromedica) |
| Journal's citation record | 0 / 4 | Archiv Euromedica: journal h-index 25 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A meta-analysis pooling many studies |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | A review of other studies — randomisation is not credited here |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 0 / 3 | Medical University of Lodz: institution h-index 320 (OpenAlex) |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 42 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 42 of the 96 points we could judge it on is 44 out of 100. |
| Total | 44 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related studies in Drug development
Also in Drug development
79 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.